Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Evolus Inc EOLS

Healthcare
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EOLS)

Evolus Reports Third Quarter 2024 Results

Business Wire November 6, 2024

Evolus to Participate in Stifel 2024 Healthcare Conference

Business Wire November 1, 2024

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Business Wire October 31, 2024

Evolus Rewards(TM) Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Business Wire October 29, 2024

Evolus to Report Third Quarter Financial Results on November 6, 2024

Business Wire October 23, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 11, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 27, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Business Wire September 6, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 9, 2024
View More News ››

Opinion & Analysis (NDAQ:EOLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EOLS)

Learn to Evaluate (EOLS) using the Charts

JUST IN: $EOLS Learn to Evaluate (EOLS) using the Charts2024-02-09 01:48:00 ET Stock Traders Daily has produced this trading report...
whytestocks - February 9, 2024

Overweight Recommendation Issued On EOLS By Barclays

News; $EOLS Overweight Recommendation Issued On EOLS By Barclays2024-01-29 04:15:01 ET Barclays analyst issues OVERWEIGHT recommendation...
whytestocks - January 29, 2024

EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY

$EOLS Excited to share an article about Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric...
AviseAnalytics - August 4, 2023
View more Bullboard ››

Riley Gold Corp.

Riley Gold Corp.

Riley Gold Corp. is a gold exploration company with projects within major gold bearing trends in the state of Nevada. The ...
View More »